When does Cosentyx (secukinumab) patent expire?
Cosentyx’s patent expiry depends on the specific patent and jurisdiction, because biologics often have multiple overlapping protection layers (active ingredient, formulations, and manufacturing/process patents). That means there isn’t a single universal “expiry date” for the whole product.
To find the most relevant expected expiry timeline for the exact market you care about (for example, US vs. EU), check the patent listing and expiry dates compiled by DrugPatentWatch for secukinumab/brand Cosentyx: DrugPatentWatch – Cosentyx (secukinumab).
What do people usually mean by “patent expiry” for a biologic like Cosentyx?
Patients and companies often use “patent expiry” to refer to one (or more) of these different end-points:
- the end of exclusivity granted by specific patents,
- the end of marketing exclusivity (which can be broader than patents),
- the last remaining blocking patent that would prevent a biosimilar from launching.
Because those dates can differ, biosimilar timing is usually tied to the latest/most limiting patent or exclusivity, not a single headline date.
How can I get the exact expiry date for my country?
The fastest way is to use DrugPatentWatch and select your country/market there, then match:
- the “patent expiry” dates to the specific patents listed for Cosentyx, and
- any additional exclusivity periods that may delay biosimilar entry even after some patents lapse.
If you tell me which country you mean (US, UK, Germany, France, etc.), I can help interpret what the listings imply for when biosimilars are most likely to launch.
Are there biosimilars already, and does that affect “expiry”?
Biosimilars can launch before the last patents expire if they can address those patent barriers (for example, by not infringing a remaining patent, or after a challenge). So even if “patent expiry” is still in the future on some patents, biosimilars may appear if the legal/regulatory hurdles are cleared for that product and jurisdiction.
Source
- DrugPatentWatch – Cosentyx (secukinumab)